Diffusion and Protein Corona Formation of Lipid-Based Nanoparticles in the Vitreous Humor: Profiling and Pharmacokinetic Considerations

The vitreous humor is the first barrier encountered by intravitreally injected nanoparticles. Lipid-based nanoparticles in the vitreous are studied by evaluating their diffusion with single-particle tracking technology and by characterizing their protein coronae with surface plasmon resonance and high-resolution proteomics. Single-particle tracking results indicate that the vitreal mobility of the formulations is dependent on their charge. Anionic and neutral formulations are mobile, whereas larger (>200 nm) neutral particles have restricted diffusion, and cationic particles are immobilized in the vitreous. PEGylation increases the mobility of cationic and larger neutral formulations but does not affect anionic and smaller neutral particles. Convection has a significant role in the pharmacokinetics of nanoparticles, whereas diffusion drives the transport of antibodies. Surface plasmon resonance studies determine that the vitreal corona of anionic formulations is sparse. Proteomics data reveals 76 differentially abundant proteins, whose enrichment is specific to either the hard or the soft corona. PEGylation does not affect protein enrichment. This suggests that protein-specific rather than formulation-specific factors are drivers of protein adsorption on nanoparticles in the vitreous. In summary, our findings contribute to understanding the pharmacokinetics of nanoparticles in the vitreous and help advance the development of nanoparticle-based treatments for eye diseases.

Publication year: 2020
Authors: Tavakoli S 1., Kari O.K. 1, Turunen T. 1, Lajunen T. 1, Schmitt M. 1, Lehtinen J. 1, Tasaka F. 2, Parkkila P. 1, Ndika J. 3, Viitala T. 1, Alenius H. 3,5, Urtti, A. 1,6,7 Subriz A. *7
Affiliations:

1 − Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland

2  − Pharmaceutics & Pharmacology Department, Global R&D, Santen Pharmaceutical Co., Ltd., Ikoma, Nara 630-0101, Japan

3 − Human Microbiome Research, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland

4  − Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland

5  –  Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden

6 – Institute of Chemistry, St. Petersburg State University, 198504 St. Petersburg, Russia

7 – School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland

Published in: Molecular Pharmaceutics, 2020
DOI: 10.1021/acs.molpharmaceut.0c00411

MP-SPR KEYWORDS

bound mass liposomes ocular drug delivery protein corona on nanoparticle thickness of protein layer undiluted vitreous

Share

Other publications